Introduction
Neuroinflammation can be defined as a local increase in glial cell activation and occasionally, an influx of immune cells into the central nervous system (CNS). Local microglia and astrocytes, and infiltrated macrophages are the main effectors of the innate immune response in the CNS. During neuroinflammation, they release different pro-inflammatory mediators, including cytokines, nitric oxide and reactive oxygen species. 1 These phenomena are observed under various neuropathological conditions and considered to be the common denominator in a number of neurological diseases with a different etiology including Alzheimer's disease, stroke, meningitis and multiple sclerosis (MS). [2] [3] [4] [5] Similar neuroinflammatory responses can be mimicked in the CNS of rats treated with a bacterial component, that is, lipopolysaccharide (LPS) or the pro-inflammatory cytokine interleukin-1 (IL-1). Peripheral or central administration of LPS or IL-1b induces a clear activation of microglial and astroglial cells, and the production of, for example, interleukin-6 (IL-6), tumor necrosis factor a (TNFa) and nitric oxide. [6] [7] [8] Although inflammatory mediators are of importance for their restorative actions under restricted inflammatory conditions in the brain, 9 they become detrimental in a situation of uncontrolled production by activated glial cells and infiltrated monocytes. 10 Indeed, cognitive impairments, demyelination, disturbances in, for example, sensory and motor movement function and eventually neuronal cell death have been reported. 1, 11 To balance the pro-inflammatory cascade of responses, an enhanced anti-inflammatory response is found in the brains of LPS or IL-1-treated rats 8, 12, 13 as well as in experimental models for MS and Alzheimer's disease.
effects. [16] [17] [18] Strengthening the anti-inflammatory response within the CNS might therefore be an attractive therapeutic strategy to reduce the production and/or action of pro-inflammatory mediators and to diminish the related pathophysiological responses.
On the basis of the observations by several research groups, IL-1ra and IL-10 show face validity as therapeutic agents to counteract production and/or action of inflammatory mediators. [19] [20] [21] [22] IL-1ra acts as a true receptor antagonist by binding to the signalling IL-1 type I receptor thereby preventing binding of both IL-1a and IL-1b to their cell surface receptor and subsequent IL-1 actions. 23 IL-10 has a broader spectrum of anti-inflammatory activities because it suppresses the production of a whole number of pro-inflammatory cytokines (for example, interferon-g, IL-1a, IL-1b, IL-2, IL-6, IL-8 and TNF-a) and nitric oxide in different cell types, including glial cells, and B-and T-lymphocytes. [24] [25] [26] Treatment with recombinant IL-1ra or IL-10 has been shown to be effective after either peripheral or central administration by reducing the levels or actions of proinflammatory cytokines in animal models, for example, sepsis, 27, 28 20, 36 and behavioral changes. 37 In situations of sustained pro-inflammatory responses within the CNS, a treatment protocol that allows longterm molecular delivery is required. To achieve this, a local gene therapeutic strategy is of particular interest as it has the potential to deliver and express a gene for extended periods of time. Lentiviral (LV) vectors are among the most promising gene therapy vectors for gene delivery into the brain [38] [39] [40] [41] LV vectors do not initiate an immunological response that compromises the viability of transduced cells, 42 and transduce non-proliferating cells, 43 which are commonly present within the CNS. Therefore, the use of these vectors may represent a powerful strategy for prolonged delivery of antiinflammatory cytokines as IL-1ra and IL-10 into the CNS.
In this study, we examined the cellular production and release of LV-derived rat IL-1ra (LV-rIL-1ra) and rat IL-10 (LV-rIL-10). Subsequently, we studied the effects of LVrIL-1ra or LV-rIL-10 on the production of pro-inflammatory mediators in LPS or IL-1b-stimulated macrophages or glial cells, respectively. Furthermore, the cellular localization of centrally administered LV-rIL-10 or LV-rIL-1ra was determined, as well as their effect on the expression of pro-and anti-inflammatory mediators within various brain regions and pituitary gland and/ or spleen of LPS or IL-1b-treated rats. Moreover, we studied the effects of LV-rIL-1ra or LV-rIL-10 on the clinical outcome in an animal model for MS.
Results

Time-dependent cytokine production by LV-transduced rat cells
We analyzed the time-course of LV vector-directed expression of rIL-1ra or rIL-10 in rat cell-lines that are relevant in neuroinflammatory processes, that is, macrophages (NR8383) and astroglial cells (C6). To this end, we have produced LV vectors containing rat IL-10 (rIL-10), rat IL-1ra (rIL-1ra) or green fluorescent protein (GFP) coding sequences under the control of the ubiquitous cytomegalovirus promoter. C6 cells and NR8383 cells were transduced with LV-GFP and LV-rIL-1ra or with LV-GFP and LV-rIL-10, respectively. Transduction efficiency was nearly 100% as determined microscopically in LV-GFP-transduced NR8383 and C6 cells (data not shown). No cytotoxic effects of LV-GFP, LV-rIL-10 or LV-rIL-1ra at 1, 4 and 7 days after transduction were detected using an MTT assay (Supplementary Figure 1) . Subsequently, rIL-1ra and rIL-10 released in the culture Figure 1 Time-dependent cytokine production by LV-transduced rat cells. Rat IL-10 and rat IL-1ra were amplified using complementary DNA prepared from rat liver and cloned into the pRRLsin transfer plasmids (pRRLsin-PPThCMV-wpre). LVs were produced by transfection of the transfer plasmids (pRRLsin-PPThCMV-transgene-wpre) in combination with the viral core packaging construct pCMVdeltaR8.74 (pPack) and the vesicular stomatitis virus G (VSV-G) envelope protein vector pMD2.G (pEnv). The production of LV-GFP was described before. 72 Determination of transducing units (TU) was performed on human embryonic kidney (HEK) 293T cells transducing them with 10-fold dilution series of viral vectors ranging from 1 Â 10 3 to 1 Â 10 6 . At 48 h after transduction, the cells were immunocytochemically stained with antibodies corresponding to the gene that was overexpressed, that is, GFP (rabbit ant-GFP, Chemicon, Hofheim, Germany, 1:500), rIL-10 (goat anti-rat IL10, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, 1:100) and rIL-1ra (sheep anti-rat IL-1ra, NIBSC, Potters Bar, UK, 1:1000). The number of transduced cells was counted in several fields throughout with a 10 Â objective (visible field is 2 mm 2 ) and TU was determined using the following formula: TU ml -1 ¼ mean cells/field Â dilution factor Â 100 Â volume (ml). Titers were usually around 10 9 TU ml -1
. Subsequently, NR8383 and C6 cells (1 Â 10 4 ) were seeded in 24-well plates with 0.5 ml of the appropriate culture media 1 day before transduction. Infectious particles were added to the cells using 0.1 ml virus, corresponding to 1 Â 10 5 TU as determined by virus titration. The media were harvested at day 4, 7 and 10 after transduction for cytokine measurement. Cytokine production at each time-point was measured in triplicate. All data were corrected for the time-dependent total cellular protein content. Rat IL-10 (a), and IL-1ra (b) concentrations were measured in cell culture supernatants by rat-specific enzyme-linked immunosorbent assays (NIBSC). 73 Data are presented from two separate experiments as mean ± s.e.m. (n ¼ 6) and are expressed as pg ml -1 . *Po0.05, **Po0.001 vs non-transduced cells. Abbreviation: Vd, virally derived.
Anti-inflammatory effect in rat glial cells and macrophages ME van Strien et al media was measured. Both proteins were released in a time-dependent manner ( Figure 1 ). Transduction of NR8383 cells with LV-rIL-10 or LV-GFP resulted both in IL-10 production. The LV-GFP-induced production of rIL-10 was also observed in transduced C6 and 293T cells (data not shown). Importantly, the levels of rIL-10 released by the LV-rIL-10-transduced NR8383 cells were up to 600% higher (in the range from 4 to 10 days) compared with the LV-GFP-transduced cells (Figure 1a ). C6 cells (and NR8383 and 293T cells, data not shown) transduced with LV-GFP did not give an increase in rIL-1ra production at any time point measured, whereas C6 cells transduced with LV-rIL-1ra produced rIL-1ra in a time-dependent manner. At 4 days post-transduction, a dramatic increase (B7000%) in virally produced IL-1ra was found compared with LV-GFP and non-transduced cells. This IL-1ra production reached a plateau level 7 days after transduction (B8000%) and remained elevated until 10 days after transduction (Figure 1b ). This time-dependent transduction and subsequent protein production by LV-transduced macrophages and astrocytes are in line with previous observations.
44-46
Biological activity of LV-mediated production of cytokines in vitro
To analyze whether cells transduced with LV-rIL-10 or LV-rIL-1ra express biologically active IL-10 and IL-1ra, we designed two functional bioassays. NR8383 were transduced with LV-rIL-10, whereas C6 cells were transduced with LV-rIL-1ra. After 3, 6 and 9 days, the cells were treated with either LPS (NR8383) or rIL-1b/ forskolin (C6) for 24 h. Subsequently, levels of TNFa produced by NR8383 cells and IL-6 levels by C6 cells were measured. This assay design was chosen based on previously published data that recombinant IL-10 can attenuate LPS-induced TNFa production in macrophagelike cells, 25 and that recombinant IL-1ra can reduce IL-1-induced effects, for example, IL-6 production in astrocytes. 47 Levels of virally derived GFP, rIL-10 and Figure 2 Biological activity of LV-rIL-10 and LV-rIL-1ra in vitro. The biological activity of the anti-inflammatory cytokines produced from the different viral vectors was tested in vitro using LPS-stimulated NR8383 (for rIL-10) and rIL-1b/forskolin-stimulated C6 (for rIL-1ra) cells. NR8383 or C6 cells (1 Â 10 5 cells per well seeded in triplo in a 12-wells plate) were transduced with LV-rIL-10 or LV-GFP (NR8383) 3, 6 and 9 days before treatment with LPS (100 ng ml -1 , Escherichia coli serotype 0128-B12; Sigma, St Louis, MO, USA) or with LV-rIL-1ra or LV-GFP (C6) 3, 6 and 9 days before treatment with rIL-1b (Glaxo Imb, Geneva, Switzerland, 0.1 ng ml -1 )/forskolin (Sigma-Aldrich, St Louis, MO, USA, 5 mM). At 24 h after stimulation, the media were collected and the protein levels of (a) TNFa (NR8383) or (b) IL-6 (C6) were measured by specific enzyme-linked immunosorbent assays. [73] [74] [75] As control, non-transduced cells were cultured and treated with the same stimuli. Data are presented as mean±s.e.m. (n ¼ 6) and are expressed as % compared with non-transduced cells. *Po0.05, **Po0.001 vs non-transduced cells. Figure 3 Localization of GFP, rIL-10 and rIL-1ra after intraparenchymal or intracerebroventricular (i.c.v.) LV administration. Adult male Wistar rats (Harlan CBP) were anaesthetized with isofluorane and stereotaxically injected unilaterally with 5 ml LV-GFP (n ¼ 2), LV-rIL-1ra (n ¼ 3) or LV-rIL-10 (n ¼ 3) (corresponding to approximately 5 Â 10 6 TU) into the brain at the level of the hippocampus/corpus callosum (3 mm anterior to bregma, 1.5 mm lateral and 5 mm ventral) according to Paxinos and Watson. 76 Another group of animals was injected in the right lateral ventricle (0.6 mm posterior to bregma, 1.5 mm lateral and 3.7 mm ventral under the brain surface) with 5 ml LV-GFP (n ¼ 2), LV-rIL-1ra (n ¼ 3) or LV-rIL-10 (n ¼ 3). Five days after injection, the rats were perfusion fixed with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.6). All experimental procedures were approved by the animal experiment committee of the VU University Medical Center. To localize viral vector-mediated produced proteins, frozen sections of 14 mm were cut in the area of the injection site on a cryostat (Microm HM 500 M, Adamas Instrumenten BV, Rhenen, The Netherlands). The sections were incubated with a rabbit anti-GFP antibody (final dilution 1/1000, Chemicon), a sheep anti-rat IL-1ra antibody (S373/B1, 1.5 mg ml -1 , final dilution 1/1000, NIBSC) or a goat anti-rat IL-10 antibody (final dilution 1/100, Santa Cruz Biotechnology Inc.) using the biotin-avidin-peroxidase method, as previously described. 15 All the sections were analyzed with light microscopy (Vanox, Olympus, Tokyo, Japan) and the sections shown are representative of those obtained in the proximity of each injected site or the contralateral side in all animals in the experimental group. For immunofluorescent double staining of GFP and ED1-positive macrophages/microglial cells, sections were co-incubated with the rabbit anti-GFP antibody (final dilution 1/250, Chemicon) and mouse monoclonal ED1 (final dilution 1:250, kind gift from Molecular Cell Biology department at the VU University Medical Center, Amsterdam, The Netherlands). Subsequently, the sections were incubated with the following appropriate set of secondary antibodies: donkey anti rabbit Alexa 488 (GFP) and donkey anti mouse Alexa 594 (ED1) (Invitrogen, Carlsbad, CA, USA; final dilution 1:400). Anti-inflammatory effect in rat glial cells and macrophages ME van Strien et al rIL-1ra were similar as shown in Figure 1 (data not shown). Non-transduced NR8383 cells treated with LPS produced TNFa levels that ranged from 1500 pg ml -1 at day 4 to 5900 pg ml -1 at day 10. This time-dependent increase is due to proliferation of NR8383 cells resulting in more cells to produce TNFa. The same holds true for the time-dependent increase in IL-1b/forskolin-induced IL-6 production in non-transduced C6 cells. IL-6 levels ranged from 250 pg ml -1 at day 4 to 1700 pg ml -1 at day 10. At day 4, 7 and 10 post-transduction, LV-GFPtransduced cells produced similar levels of TNFa or IL-6 as produced by non-transduced cells (Figures 2a  and b) . Of particular interest is that in LV-GFPtransduced NR8383 cells no effect on LPS-induced TNFa production was observed (Figure 2a) , indicating that the LV-GFP-induced rIL-10 production in NR8383 cells (Figure 1a) is not biologically relevant. Importantly, the amount of TNFa produced and released by LPS Anti-inflammatory effect in rat glial cells and macrophages ME van Strien et al stimulated, LV-rIL-10-transduced NR8383 cells was dramatically lower at all time-points measured (Figure 2a) . That IL-10 reduces TNFa production corresponds to observations by us and others using maximally 48-h treatment with recombinant IL-10. 20, 48 The present data indicate that LV-rIL-10 transduction of inflammation relevant macrophages result in relatively long-term expression of rIL-10 that is biologically active. In C6 cells, the IL-1b/forskolin-stimulated IL-6 production was significantly attenuated in LV-rIL-1ra-transduced cells at 7 and 10 days post-transduction (Figure 2b) . LV-rIL-1ra-transduced C6 cells expressed levels of rIL-1ra (Figure 1b) that are approximately 100-fold excess over the amount of IL-1 added (100 pg ml -1 ) to induce IL-6 production. This amount of rIL-1ra is able to reduce IL-1-induced IL-6 production ( Figure 2b ). Indeed, it is known from in vivo and in vitro studies that, because of competition for the same IL-1 type I receptor, an excess of IL-1ra over IL-1 is necessary to attenuate IL-1 effects. 49 These observations show that IL-1ra produced after viral transduction of astroglial cells is biologically active, but it takes approximately 4-7 days after transduction before virally produced rIL-1ra can counteract IL-1-induced production of IL-6. Whether this is due to the levels of rIL-1ra reached or its biological activity at that time remains unclear.
Cellular localization of GFP, rIL-10 and rIL-1ra in vivo after intraparenchymal and intracerebroventricular (i.c.v.) administration of LV vectors
As LV vectors do not pass the blood-brain barrier, we subsequently examined if intraparenchymal or i.c.v. injection of LV-rIL-1ra, LV-rIL-10 or LV-GFP resulted in transgene expression in the rat brain in vivo. At 5 days after intraparenchymal injection of each of the three LV vectors, GFP (Figures 3a-c) , IL-10 ( Figure 3d ) or IL-1ra (Figure 3e ) immunopositive cells were identified at the ipsilateral side. In contrast, IL-10 or IL-1ra immunopositive cells were absent at the contralateral side ( Figures  3f and g ), indicating that protein production was due to LV overexpression of the transgene. The time-frame was chosen based on our in vitro observations that it takes more than 4 days to reach levels of rIL-1ra in C6 astrocytes that is biologically active. After intraparenchymal injection, transduced cells were localized predominantly in the area surrounding the injection site and based on their morphology, most transduced cells are glial cells (Figures 3b and c) . Although, we cannot exclude the transduction of neurons by LV [50] [51] [52] it is of interest that, besides neurons, glial cells are transduced by LV 53, 54 because in various neurological disorders these cell types are involved in the pathological process and, in addition to infiltrating immune cells, are important producers of pro-inflammatory mediators. In contrast to LV vectors, most adeno-associated viral vectors, used for gene therapy in the brain, preferentially transduce neurons. 55 In addition, we studied the distribution and cellular localization of transgene expression after injection in the lateral ventricle of rats. Previous studies showed that other viral vectors administered intrathecally induced transgene expression in, not further characterized, cells lining the ventricular ependyma. 56, 57 We identified that i.c.v. administration of LV vectors particularly transduced macrophages lining the ventricular walls and in the meninges, as identified by immunohistochemical double labelling with ED1, a marker for macrophages. These cells expressed the transgenes of interest (Figures 3h-k) . Our LV vectors can therefore be considered as useful tools to centrally deliver genes encoding anti-inflammatory proteins in rat models for neurological diseases that are characterized by the production of inflammatory mediators in glial cells and/or (meningeal) macrophages.
LV-mediated expression of anti-inflammatory cytokines in vivo counteracts production and/or action of pro-inflammatory mediators in rat brain, but not in the periphery
To study the anti-inflammatory effects of LV-mediated expression of rIL-10 or rIL-1ra within the CNS, LV Figure 4 Effect of central administration of LV vectors on mRNA levels of TNFa, rIL-6 and iNOS. Adult male Wistar rats (Harlan CBP) were anesthetized with ketamin (Kombivet, Etten-Leur, The Netherlands, 50 mg kg -1 , intramuscular (i.m.)) and xyzaline (Rompun, Bayer, Leverkusen, Germany, 5 mg kg -1 , intraperitoneal (i.p.)) and a permanent 22-gauge guide cannula with an indwelling dummy cannula (Plastics One, Roanoke, VA, USA) was implanted into the right lateral ventricle of the brain at stereotaxic coordinates: 0.6 mm posterior to the bregma, 1.5 mm lateral and 3.7 mm under the brain surface. After surgery, rats were individually housed and allowed to recover for at least 6 days. Rats were given LV-GFP (n ¼ 12), LV-rIL-1ra (n ¼ 6) or LV-IL-10 (n ¼ 6) (5 ml corresponding to approximately 5 Â 10 6 TU) on day 0 via continuous i.c.v. (lateral ventricle) infusion to freely moving rats at a flow rate of 5 ml min -1 using a microsyringe infusion pump (Harvard Apparatus Inc., South Natick, MA, USA). On day 5, the animals infected with LV-rIL-10 (n ¼ 6) or LV-GFP (n ¼ 6) were injected i.c.v. with LPS (60 ng in 10 ml PBS, 5 ml min -1 ) (a, c, e, g). The animals infected with LV-rIL-1ra (n ¼ 6) or LV-GFP (n ¼ 6) were injected i.c.v. with recombinant rat IL-1b (100 ng in 10 ml PBS, 5 ml min -1 ) (b, d, f, h). Animals were killed 4 h after treatment and different brain regions were dissected, split in two anatomically equal portions to be used for either protein or mRNA analysis. All experimental procedures were approved by the animal experiment committee of the VU University Medical Center. Transcript levels of TNFa (LV-rIL-10) or IL-6 (LV-rIL-1ra) and iNOS were measured by real time quantitative PCR in rat cortex (a, b), hippocampus (c, d), hypothalamus (e, f), pituitary gland (g, h) and spleen (i, j). To allow RNA analysis, brain tissues were homogenized in Trizol reagent (Invitrogen) and RNA was isolated as described by the manufacturer. In all, 1 ml of RNA was reverse transcribed into complementary DNA (cDNA) using the reverse transcription system (Promega Benelux b.v., Leiden, The Netherlands) with oligo-dT primers and AMV enzyme, according to the manufacturer's instructions. For real-time quantitative PCR, the SYBR Green PCR Core reagents kit (Applied Biosystems, Foster City, CA, USA) was used in combination with the following rat primers: GAPDH forward In parallel with these data, animals transduced with LV-rIL-10 or LV-rIL-1ra produced 30-40% less TNFa and 50-75% less IL-6 protein in cortex and hippocampus compared with LV-GFP-transduced animals ( Figure 5 ). After i.c.v. administration of LV vectors, the virally derived proteins produced by cells lining the ventricular walls can be released and diffuse into the brain parenchyma to reach the various brain regions through volume transmission as shown for the cytokine IL-1b. 58 This mechanism probably underlies the anatomical spatially generalized anti-inflammatory effect that we observed within the CNS. Importantly, LV-derived rIL-10 and rIL-1ra produced within the CNS did not affect TNFa, IL-6 or iNOS mRNA levels in the tissues studied that lie outside the blood-brain barrier, that is, the pituitary gland and spleen, (Figures 4g-j) , indicating the centrally localized action of LV-derived proteins. In contrast, centrally administered LPS or IL-1b resulted in clearly detectable production of IL-6 and iNOS, but not of TNFa, in the spleen and to a lesser extent in the pituitary gland, which is in agreement with previous observations. 59, 60 In addition, we studied whether LV-rIL-10 altered the expression levels of the anti-inflammatory cytokines IL-4 and transforming growth factor (TGF)b. Adenoviral vectors expressing IL-10 have been shown to enhance the expression of TGFb in cardiac allografts 61 or IL-4 in lymph nodes of parasite-infected mice. 62 In this study, we neither observed an increase nor a decrease in IL-4 or TGFb expression in the CNS or pituitary gland of LV-rIL-10-treated rats (Supplementary Figure 2) . rIL-1ra produced by LV-rIL-1ra acts as a true receptor antagonist and is thus not expected to have agonistic properties. 49 The fact that IL-10 produced by LV-IL-10 does not affect IL-4 and TGFb levels within the CNS may be due to the low presence of T-lymphocytes particularly known to produce IL-4. 63 and to the low reactivity of astrocytes, producing TGFb, in response to LPS. 64, 65 Thus, our data indicate that LV expression of rIL-10 or rIL-1ra within the CNS is very effective in attenuating TNFa, IL-6 and iNOS, but not IL-4 and TGFb production, within the brain, and leaving peripheral production of the pro-inflammatory mediators intact. Recently, LV vectors expressing IL-10 or IL-1ra have been used to locally treat endotoxin-induced uveitis and it was shown not to affect the systemic immune response. 66 This is of importance when applying a chronic, but also acute antiinflammatory therapy to counteract neuroinflammatory processes or shifting the immune balance to an antiinflammatory state that might, in the long term, result in unwanted peripheral side effects. 66, 67 LV-mediated expression of anti-inflammatory cytokines in vivo reduces clinical pathology of experimental MS To determine whether LV-rIL10 and LV-rIL-1ra have relatively long-lasting effects in a more clinical relevant setting, we used rats suffering from chronic-relapsing experimental autoimmune encephalomyelitis (cr-EAE), an animal model mimicking various aspects of multiple sclerosis. 68 Cr-EAE animals were treated i.c.v. with LV-GFP, LV-rIL10 or LV-rIL-1ra at the remission phase of the disease, and clinical scores were determined before, and for 10 days after viral transduction ( Figure 6 ). The mean clinical score during the relapse of cr-EAE (days 18-26) animals transduced with LV-GFP was 2.5 ( Figure 6a ) compared with 0.75 for animals transduced with LV-rIL-10 ( Figure 6b ) and 0.85 for animals transduced Figure 5 Effect of central administration of LV-rIL-10 and LV-rIL-1ra on protein expression levels of TNFa or IL-6 respectively. To determine cytokine protein levels, the dissected brain regions were homogenized in lysis buffer containing 10 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 100 mM phenylmethylsulphonyl fluoride, 10 mg ml -1 leupeptin, 10 mg ml -1 pepstatin and 10 mg ml Anti-inflammatory effect in rat glial cells and macrophages ME van Strien et al with LV-rIL-1ra (Figure 6c ). The data obtained showed that central application of LV-rIL10 or LV-rIL-1ra at a clinically relevant moment, that is, when disease is already ongoing, had beneficial effects on the clinical outcome of cr-EAE. This is of interest as it has previously been shown that viral vector-mediated expression of IL-1ra reduced clinical symptoms in chronic mouse EAE when treated before the onset of disease but did not induce relieve of symptoms when disease was already ongoing. 56 In contrast, using an adenoviral vector expressing human IL-10, therapeutic effects in chronic mouse EAE were observed. 69 This study showed that rIL-1ra or rIL-10 when overexpressed within the CNS during the remission phase of disease by means of a LV vector, clearly reduced clinical symptoms during the relapse, supporting the role of locally produced pro-inflammatory cytokines, including IL-1, in the relapse phase of cr-EAE. Although we are aware of the limitations when extrapolating results obtained by viral vectormediated gene expression in animal models to the real human disease, as shown for other MS treatments 70, 71 we consider the use of low immunogenic LV vectors expressing either IL-10 or IL-1ra of therapeutic interest to prevent relapses in human MS.
In summary, we observed LV-mediated production of the anti-inflammatory cytokines IL-10 and IL-1ra in neuroinflammation relevant glial cells and macrophages. The LV-mediated anti-inflammatory cytokines produced were biologically active and able to attenuate the production of TNFa, IL-6 and iNOS, but not IL-4 and TGFb within the CNS without affecting the production of these mediators in the periphery. Furthermore, in a clinical relevant setting when the LV vectors were injected during remission of cr-EAE, clinical scores were attenuated during relapse of the disease. We put forward that application of LV vectors encoding IL-10 or IL-1ra within the CNS reduce neuroinflammatory responses and thereby have the potential to curtail immune-mediated neuropathological responses without interfering with the peripheral production of pro-inflammatory mediators.
